Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31753727

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jan
First author
Petrylak DP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):11-13. doi: 10.1016/S1470-2045(19)30661-8.
    note
    Source null
    related pmid
    31753728
    relationship
    Comment in

Authors and identifiers

  1. name
    Petrylak DP
    type
    Author
  2. name
    de Wit R
    type
    Author
  3. name
    Chi KN
    type
    Author
  4. name
    Drakaki A
    type
    Author
  5. name
    Sternberg CN
    type
    Author
  6. name
    Nishiyama H
    type
    Author
  7. name
    Castellano D
    type
    Author
  8. name
    Hussain SA
    type
    Author
  9. name
    Fléchon A
    type
    Author
  10. name
    Bamias A
    type
    Author
  11. name
    Yu EY
    type
    Author
  12. name
    van der Heijden MS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Petrylak DP
    type
    Author
  2. name
    de Wit R
    type
    Author
  3. name
    Chi KN
    type
    Author
  4. name
    Drakaki A
    type
    Author
  5. name
    Sternberg CN
    type
    Author
  6. name
    Nishiyama H
    type
    Author
  7. name
    Castellano D
    type
    Author
  8. name
    Hussain SA
    type
    Author
  9. name
    Fléchon A
    type
    Author
  10. name
    Bamias A
    type
    Author
  11. name
    Yu EY
    type
    Author
  12. name
    van der Heijden MS
    type
    Author
bibliography ids
  1. nci-bib-f929f940ba26645556b7446e
book metadata
content sha256
594a4cbcac4d77ef04ee17932fbf7ab698ddf85673dbe772bde7a67bfdb059be
document type
citation
dois
  1. 10.1016/S1470-2045(19)30668-0
electronic publication date
display
2019 Nov 18
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31753727
immutable id
pubmed:31753727@594a4cbcac4d77ef04ee17932fbf7ab698ddf85673dbe772bde7a67bfdb059be
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
105-120
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):11-13. doi: 10.1016/S1470-2045(19)30661-8.
    note
    Source null
    related pmid
    31753728
    relationship
    Comment in
outcomes validated
false
pmid
31753727
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
c40af67adff954fd0c05fb24266a8e409d59edcceded1001b9a999ec06cb6d91
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Jan
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31753727/
title
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice